Lobaplatin
- Generic Name
- Lobaplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H18N2O3Pt
- CAS Number
- 135558-11-1
- Unique Ingredient Identifier
- OX5XK1JD8C
- Background
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
- Indication
主要用于治疗乳腺癌、小细胞肺癌及慢性粒细胞白血病。
- Associated Conditions
- -
- Associated Therapies
- -
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06714383
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 46
- Registration Number
- NCT06170697
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 132
- Registration Number
- NCT05780294
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05766605
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05701436
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05546255
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 201
- Registration Number
- NCT04845490
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 231
- Registration Number
- NCT04808466
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 60
- Registration Number
- NCT03700359
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 733
- Registration Number
- NCT03413436
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.